IMCR
Immunocore Holdings LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.62B
P/E Ratio
—
EPS
$-0.71
Beta
0.83
52W High
$40.71
52W Low
$24.61
50-Day MA
$31.99
200-Day MA
$33.76
Dividend Yield
—
Profit Margin
-8.88%
Forward P/E
625.00
PEG Ratio
—
About Immunocore Holdings Ltd
Immunocore Holdings Limited, an advanced stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious and autoimmune diseases. The company is headquartered in Abingdon, the United Kingdom.
Fundamentals
| Revenue (TTM) | $400.02M |
| Gross Profit (TTM) | $386.15M |
| EBITDA | $-22.36M |
| Operating Margin | 0.04% |
| Return on Equity | -9.58% |
| Return on Assets | -1.54% |
| Revenue/Share (TTM) | $7.95 |
| Book Value | $7.52 |
| Price-to-Book | 4.10 |
| Price-to-Sales (TTM) | 4.05 |
| EV/Revenue | 2.838 |
| EV/EBITDA | -45.82 |
| Quarterly Earnings Growth (YoY) | 822.00% |
| Quarterly Revenue Growth (YoY) | 24.30% |
| Shares Outstanding | $50.70M |
| Float | $45.06M |
| % Insiders | 0.07% |
| % Institutions | 99.19% |
Analyst Ratings
Consensus ($63.86 target)
1
Strong Buy11
Buy3
HoldData last updated: 4/8/2026